In tumor with FGFR2 amplification, trials on the efficacy of inhibitors of FGFR2, such as Dovitinib (NCT01719549) or AZD4547 (NCT01457846), are ongoing in the metastatic setting and, therefore, are far away to be tested in resectable gastric cancer. Here, FGFR2 is linked to neoplasm.